TD Private Client Wealth’s Altimmune ALT Stock Holding History

TD Private Client Wealth’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-193	Closed	-$697	–	1655
2025 Q4	$697	Buy	+193	New	+$841	﹤0.01%	1440

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TD Private Client Wealth's ALT Position: Q1 2026 in Review

TD Private Client Wealth sold out of Altimmune (ALT) in Q1 2026, closing a stake of 193 shares — an estimated $697 sold.

TD Private Client Wealth first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $697 in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

TD Private Client Wealth reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
TD Private Client Wealth sold 193 Altimmune shares in Q1 2026, an estimated $697.
TD Private Client Wealth first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
TD Private Client Wealth's Altimmune position peaked at $697 in Q4 2025.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.